1 Centre for Neuroscience and Trauma, BICMS, Barts and the London School of Medicine and Dentistry, London, UK.
2 University of Münster, Medical Faculty, Germany.
Cephalalgia. 2017 Oct;37(11):1106-1108. doi: 10.1177/0333102416660551. Epub 2016 Jul 21.
Background Methysergide has been as an effective treatment for migraine and cluster headache for over 50 years but has recently been investigated by the European Medicines Agency due to safety concerns. Methods To assess the need for continuing availability of methysergide, the International Headache Society performed an electronic survey among their members. Results The survey revealed that 71.3% of all respondents had ever prescribed methysergide and 79.8% would prescribe it if it were to become available. Respondents used it more in cluster headache than migraine, and reserved it for use in refractory patients. Conclusion The vast majority of headache experts in this survey regarded methysergide a unique treatment option for specific populations for which there are no alternatives, with an urgent need to continue its availability. This position was supported by the International Headache Society.
美西麦角用于治疗偏头痛和丛集性头痛已有超过 50 年的历史，但由于安全性问题，最近受到欧洲药品管理局的调查。
为评估继续提供美西麦角的必要性，国际头痛学会对其成员进行了电子调查。
调查显示，所有受访者中有 71.3%的人曾开处过美西麦角，如果该药上市，79.8%的人会开。受访者在丛集性头痛中比偏头痛中更常使用该药，并将其保留给难治性患者使用。
在这项调查中，绝大多数头痛专家认为美西麦角是特定人群的独特治疗选择，目前尚无替代药物，迫切需要继续提供该药。国际头痛学会支持这一立场。
